Peretz 1995.

Methods	RCT.
Participants	521 patients with relapsed breast cancer
Interventions	Single agent paclitaxel at standard dose (175mg/ m2). 3 versus 24 hour infusion.
Outcomes	Toxicity, response, time to progression
Notes	Abstract only, only total randomised given, no breakdown by arm. We have assumed 1:1 randomisation in this trial, but this may be misleading and should be interpreted with caution since the outcomes are reported as crude numbers rather than percentages. Objective responses were reported in 29% of women receiving an infusion of three hours duration compared with 32% of women having a 24 hour infusion. Median time to progression was 3.8 months for the three hour infusion compared to 4.6 months for a 24 hour infusion (P =0.02). Median overall survival was 9.8 months for the three hour infusion compared with 13.4 months for the 24 hour infusion (P = 0.02). After adjustment for prognostic factors these differences were not significant (time to progression P =0.08, survival P =0.10).
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial is described as randomised, but no further details are reported.
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Not reported
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists